BR112015018087A8 - composto, composição farmacêutica e uso - Google Patents

composto, composição farmacêutica e uso

Info

Publication number
BR112015018087A8
BR112015018087A8 BR112015018087A BR112015018087A BR112015018087A8 BR 112015018087 A8 BR112015018087 A8 BR 112015018087A8 BR 112015018087 A BR112015018087 A BR 112015018087A BR 112015018087 A BR112015018087 A BR 112015018087A BR 112015018087 A8 BR112015018087 A8 BR 112015018087A8
Authority
BR
Brazil
Prior art keywords
compound
compounds
pharmaceutical composition
formulations
depression
Prior art date
Application number
BR112015018087A
Other languages
English (en)
Other versions
BR112015018087B1 (pt
BR112015018087A2 (pt
Inventor
A Lowe John Iii
Amin Khan M
Original Assignee
Aptinyx Inc
Naurex Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aptinyx Inc, Naurex Inc filed Critical Aptinyx Inc
Publication of BR112015018087A2 publication Critical patent/BR112015018087A2/pt
Publication of BR112015018087A8 publication Critical patent/BR112015018087A8/pt
Publication of BR112015018087B1 publication Critical patent/BR112015018087B1/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/10—Spiro-condensed systems
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Abstract

composto, composição farmacêutica e uso. são divulgados compostos tendo potência intensificada na modulação da atividade de receptor de nmda. tais compostos são contemplados para uso no tratamento de condições tais como depressão e distúrbios relacionados. formulações oralmente disponíveis e outras formas de distribuição farmaceuticamente aceitáveis dos compostos, incluindo formulações intravenosas, são também descritas.
BR112015018087-6A 2013-01-29 2014-01-29 Compostos moduladores de receptor n-metil-d-aspartato (nmda) de espiro-lactama, composição farmacêutica e uso dos mesmos BR112015018087B1 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361757903P 2013-01-29 2013-01-29
US61/757,903 2013-01-29
PCT/US2014/013619 WO2014120783A1 (en) 2013-01-29 2014-01-29 Spiro-lactam nmda receptor modulators and uses thereof

Publications (3)

Publication Number Publication Date
BR112015018087A2 BR112015018087A2 (pt) 2017-07-18
BR112015018087A8 true BR112015018087A8 (pt) 2021-06-22
BR112015018087B1 BR112015018087B1 (pt) 2022-09-20

Family

ID=50071821

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112015018087-6A BR112015018087B1 (pt) 2013-01-29 2014-01-29 Compostos moduladores de receptor n-metil-d-aspartato (nmda) de espiro-lactama, composição farmacêutica e uso dos mesmos

Country Status (28)

Country Link
US (8) US9512134B2 (pt)
EP (2) EP2951183B1 (pt)
JP (2) JP2016506958A (pt)
KR (1) KR102280616B1 (pt)
CN (1) CN105229011B (pt)
AU (1) AU2014212484B2 (pt)
BR (1) BR112015018087B1 (pt)
CA (1) CA2898861C (pt)
CL (2) CL2015002121A1 (pt)
CY (1) CY1121675T1 (pt)
DK (1) DK2951183T3 (pt)
EA (1) EA032649B1 (pt)
ES (2) ES2935352T3 (pt)
HK (1) HK1218417A1 (pt)
HR (2) HRP20221545T1 (pt)
HU (1) HUE043843T2 (pt)
IL (1) IL240163B (pt)
LT (2) LT2951183T (pt)
MX (1) MX2015009786A (pt)
MY (1) MY188450A (pt)
PE (1) PE20151416A1 (pt)
PH (1) PH12015501601B1 (pt)
PL (1) PL2951183T3 (pt)
PT (2) PT3514158T (pt)
SG (1) SG11201505860XA (pt)
SI (2) SI3514158T1 (pt)
TR (1) TR201908596T4 (pt)
WO (1) WO2014120783A1 (pt)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102186883B (zh) 2008-09-18 2016-08-03 西北大学 Nmda受体调节剂和其用途
PE20151437A1 (es) 2013-01-29 2015-10-10 Naurex Inc Moduladores de receptores nmda de espiro-lactama y sus usos
WO2014120789A1 (en) 2013-01-29 2014-08-07 Naurex, Inc. Spiro-lactam nmda receptor modulators and uses thereof
US9828384B2 (en) 2013-01-29 2017-11-28 Aptinyx Inc. Spiro-lactam NMDA receptor modulators and uses thereof
CA2899191A1 (en) 2013-01-29 2014-08-07 Naurex, Inc. Spiro-lactam nmda receptor modulators and uses thereof
US9512134B2 (en) 2013-01-29 2016-12-06 Aptinyx, Inc. Spiro-lactam NMDA receptor modulators and uses thereof
WO2017201285A1 (en) 2016-05-19 2017-11-23 Aptinyx Inc. Spiro-lactam nmda receptor modulators and uses thereof
BR112018073663A2 (pt) * 2016-05-19 2019-04-30 Aptinyx Inc. moduladores de receptores nmda spiro-lactâmicos e seus usos
PE20190500A1 (es) 2016-08-01 2019-04-10 Aptinyx Inc Moduladores del receptor nmda spiro-lactam y uso de los mismos
PE20190503A1 (es) 2016-08-01 2019-04-10 Aptinyx Inc Moduladores del receptor nmda espiro-lactam y uso de los mismos
SG11201900546UA (en) 2016-08-01 2019-02-27 Aptinyx Inc Spiro-lactam and bis-spiro-lactam nmda receptor modulators and uses thereof
SG11201900554YA (en) 2016-08-01 2019-02-27 Aptinyx Inc Spiro-lactam nmda modulators and methods of using same
CN109890825B (zh) * 2016-08-01 2022-03-11 阿普廷伊克斯股份有限公司 螺-内酰胺nmda受体调节剂及其用途
JP7210599B2 (ja) 2018-01-31 2023-01-23 アプティニックス インコーポレイテッド スピロラクタム系ｎｍｄａ受容体修飾因子およびその使用
WO2019152685A1 (en) * 2018-01-31 2019-08-08 Aptinyx Inc. Spiro-lactam nmda receptor modulators and methods of using same
WO2019152696A1 (en) * 2018-01-31 2019-08-08 Aptinyx Inc. Spiro-lactam nmda receptor modulators and uses thereof
WO2019152688A1 (en) * 2018-01-31 2019-08-08 Aptinyx Inc. Spiro-lactam nmda receptor modulators and uses thereof
SG11202007251XA (en) * 2018-01-31 2020-08-28 Aptinyx Inc Spiro-lactam nmda receptor modulators and uses thereof
JP2022539342A (ja) * 2019-06-24 2022-09-08 ノーレックス インコーポレイテッド ｔｅｒｔ－ブチル（Ｓ）－２－（（２Ｓ，３Ｒ）－１－アミノ－３－ヒドロキシ－１－オキソブタン－２－イル）－１－オキソ－２，５－ジアザスピロ［３．４］オクタン－５－カルボキシレートの固体形態およびそれらを調製する方法
CN114269338A (zh) 2019-06-24 2022-04-01 诺雷克斯股份有限公司 生产二氮杂螺内酰胺化合物的方法和中间体
AU2020323543A1 (en) * 2019-08-01 2022-02-24 Aptinyx Inc. Methods of treating disorders associated with elevated levels of antibodies that interact with the NMDA receptor
CN113956183B (zh) * 2021-10-28 2023-06-20 成都市科隆化学品有限公司 一种Boc-Ser(Bzl)-OH及其制备方法

Family Cites Families (84)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0180398A1 (en) 1984-10-26 1986-05-07 The Regents Of The University Of California Synthesis of beta-lactam
CA1305177C (en) 1987-06-30 1992-07-14 Yasufumi Ohfune Carboxycyclopropylglycine and process for producing the same
US4904681A (en) 1987-12-01 1990-02-27 G. D. Searle & Co. D-cycloserine and its prodrugs as cognitive enhancers
EP0360390A1 (en) 1988-07-25 1990-03-28 Glaxo Group Limited Spirolactam derivatives
US5061721A (en) 1989-03-15 1991-10-29 G. D. Searle & Co. Composition containing d-cycloserine and d-alanine for memory and learning enhancement or treatment of a cognitive or psychotic disorder
US5086072A (en) 1990-06-18 1992-02-04 The United States Of America As Represented By The Department Of Health And Human Services Treatment of mood disorders with functional antagonists of the glycine/nmda receptor complex
US5350769A (en) 1990-10-30 1994-09-27 Ss Pharmaceutical Co., Ltd. Antiinflammatory gel preparation
US5168103A (en) 1991-01-22 1992-12-01 American Home Products Corporation [[2-(amino-3,4-dioxo-1-cyclobuten-1-yl) amino]alkyl]-acid derivatives
FR2692268B1 (fr) 1992-06-15 1994-08-19 Rhone Poulenc Rorer Sa Nouveaux polypeptides ayant une activité de récepteur NMDA, acides nucléiques codant pour ces polypeptides et utilisations.
SE9301667D0 (sv) 1993-05-14 1993-05-14 Kabi Pharmacia Ab New use
US5523323A (en) 1993-09-14 1996-06-04 Maccecchini; Maria-Luisa Use of partial agonists of the NMDA receptor to reduce opiate induced tolerance and dependence
US5605911A (en) 1995-01-31 1997-02-25 Washington University Use of alpha-2 adrenergic drugs to prevent adverse effects of NMDA receptor hypofunction (NRH)
US6335358B1 (en) 1995-04-12 2002-01-01 President And Fellows Of Harvard College Lactacystin analogs
US5741778A (en) 1996-03-19 1998-04-21 Amgen Inc. Method for treating Huntington's disease using glial cell line-derived neurotrophic factor (GDNF) protein product
US5763393A (en) 1996-05-17 1998-06-09 Neurotherapeutics L.P. Neuroactive peptides
US6541453B2 (en) 1996-06-07 2003-04-01 Syngenta Limited Peptide derivatives
US5959075A (en) 1996-08-02 1999-09-28 Zymogenetics, Inc. Testis-specific insulin homolog polypeptides
US5902815A (en) 1996-09-03 1999-05-11 Washington University Use of 5HT-2A serotonin agonists to prevent adverse effects of NMDA receptor hypofunction
JP3955345B2 (ja) 1996-09-27 2007-08-08 サントリー株式会社 新規アミノ酸ダイジハーベイン
AU1585999A (en) 1997-11-12 1999-05-31 Neurotherapeutics Methods for the detection and treatment of disease using a glycosyltransferase
US5952389A (en) 1998-01-13 1999-09-14 Synchroneuron Methods of treating tardive dyskinesia and other movement disorders
US6007841A (en) 1998-03-13 1999-12-28 Algos Pharmaceutical Corporation Analgesic composition and method for treating pain
US6274314B1 (en) 1998-04-02 2001-08-14 Nyxis Neurotherapies, Inc. Diagnostic assay for the modified nucleosides pseudouridine, 7-methyladenosine, or 1-methyladenosine
US6197820B1 (en) 1998-04-06 2001-03-06 Uab Research Foundation Use of phenylglycine derivatives to decrease neuronal death caused by brain tumors and brain lesions
US6025471A (en) 1998-06-03 2000-02-15 Deghenghi; Romano Diazaspiro, azepino and azabicyclo therapeutic peptides
AU1724000A (en) 1998-11-12 2000-05-29 Nyxis, Inc. Diagnostic assay for cancer
US20030064921A1 (en) 1999-10-27 2003-04-03 The Regents Of The University Of California Methods and compounds for modulating melanocortin receptor ligand binding and activity
AU1922301A (en) 1999-11-17 2001-05-30 Nyxis Neurotherapies, Inc. Differential gene expression in cancer
AU782678B2 (en) 2000-02-01 2005-08-18 Agy Therapeutics, Inc. Interaction of NMDA receptor with protein tyrosine phosphatase
AU2001268467A1 (en) 2000-06-14 2001-12-24 Nyxis Neurotherapies, Inc. Identification of genes and compounds for treatment of cancer
AU2001271366A1 (en) 2000-06-22 2002-01-02 Nyxis Neurotherapies, Inc. Neuroactive peptides for treatment of hypoxia and related conditions
GB0018272D0 (en) 2000-07-25 2000-09-13 Vernalis Research Limited Chemical compounds IV
EP1186303A3 (en) 2000-09-06 2003-12-10 Pfizer Products Inc. Pharmaceutical combinations, for the treatment of stroke and traumatic brain injury, containing a neutrophil inhibiting factor and an selective NMDA-NR2B receptor antagonist
IL145209A0 (en) 2000-09-06 2002-06-30 Pfizer Prod Inc Pharmaceutical combinations for the treatment of stroke and traumatic brain injury
UA73619C2 (en) 2000-12-13 2005-08-15 Pfizer Prod Inc Stable pharmaceutical compositions of nmda receptor agonist (variants) and method of treatment
US20020142287A1 (en) 2000-12-14 2002-10-03 Hirotaka Yamamoto High throughput assay to detect inhibitors of the map kinase pathway
US20030065138A1 (en) 2001-03-07 2003-04-03 University Of Utah Research Foundation Linear gamma-carboxyglutamate rich conotoxins
AU2002255705A1 (en) 2001-03-12 2002-09-24 Nyxis Neurotherapies, Inc Neuroactive peptides for prevention and/or treatment of hypoxia and neuropathic pain
WO2003010540A1 (en) 2001-07-25 2003-02-06 Nyxis Neurotherapies, Inc. Method of identifying nmda-related agent
NZ566367A (en) 2002-07-05 2009-04-30 Targacept Inc N-Aryl diazaspiracyclic compounds capable of affecting nicotinic cholinergic receptors and methods of preparation and use thereof
US7273889B2 (en) 2002-09-25 2007-09-25 Innovative Drug Delivery Systems, Inc. NMDA receptor antagonist formulation with reduced neurotoxicity
EP1660634A4 (en) 2003-08-08 2009-02-18 Burnham Inst P16-mediated regulation of NMDA receptors
WO2005020973A2 (en) 2003-08-29 2005-03-10 The University Of Houston System Compositions having antimycrobial activity including a hydroxamate or a hydroxamate and a hydroxylamine
GB0323204D0 (en) 2003-10-03 2003-11-05 Novartis Ag Organic compounds
US20050096311A1 (en) 2003-10-30 2005-05-05 Cns Response Compositions and methods for treatment of nervous system disorders
WO2006034196A1 (en) 2004-09-17 2006-03-30 Lifelike Biomatic Inc. Compositions for enhancing memory and methods therefor
US20090221544A1 (en) 2005-03-24 2009-09-03 Emory University Methods for the treatment of a traumatic central nervous system injury via a tapered administration protocol
CA2620361C (en) 2005-08-26 2014-10-14 Wisconsin Alumni Research Foundation Poly-beta-peptides from functionalized beta-lactam monomers and antibacterial compositions containing same
AR059224A1 (es) 2006-01-31 2008-03-19 Jerini Ag Compuestos para la inhibicion de integrinas y uso de estas
WO2007103719A2 (en) 2006-03-03 2007-09-13 Incyte Corporation MODULATORS OF 11-β HYDROXYL STEROID DEHYDROGENASE TYPE 1, PHARMACEUTICAL COMPOSITIONS THEREOF, AND METHODS OF USING THE SAME
WO2008033464A2 (en) 2006-09-15 2008-03-20 Schering Corporation Azetidinone derivatives for the treatment of disorders of the lipid metabolism
JP2008188285A (ja) 2007-02-06 2008-08-21 Bridgestone Corp バックパッド及び車両用シート
CN101066945B (zh) 2007-05-25 2010-05-19 中国科学院上海有机化学研究所 一种合成3-位取代内酰胺类化合物的方法
CN101125817B (zh) 2007-08-03 2011-09-14 中国科学院上海有机化学研究所 一种合成高对映选择性醛基取代小环胺类化合物和光学活性3-位取代内酰胺类化合物的方法
WO2009039390A2 (en) 2007-09-20 2009-03-26 Naurex Inc. The development of glycobiology-based therapeutics for the treatment of brain tumors
WO2009105718A1 (en) 2008-02-20 2009-08-27 The Children's Hospital Of Philadelphia Genetic alterations associated with autism and the autistic phenotype and methods of use thereof for the diagnosis and treatmemt of autism
AU2009264334A1 (en) 2008-06-27 2009-12-30 Neurosearch A/S Novel tetramethyl substituted piperidine derivatives and their use as monoamine neurotransmitter re-uptake inhibitors
EP2323981B1 (en) 2008-08-07 2014-03-12 F. Hoffmann-La Roche AG Process for the preparation of a macrocycle
GB0814991D0 (en) 2008-08-15 2008-09-24 Glaxo Group Ltd Compounds
CN102186883B (zh) 2008-09-18 2016-08-03 西北大学 Nmda受体调节剂和其用途
WO2010065709A2 (en) 2008-12-03 2010-06-10 Amin Khan Hydroxamic acid derivatives, preparation and therapeutic uses thereof
DE102009001460B4 (de) 2009-03-11 2010-12-02 Zf Friedrichshafen Ag Ölbehälter
US20120178695A1 (en) 2009-07-02 2012-07-12 Joseph Moskal Methods of treating neuropathic pain
EP2985032B1 (en) 2009-10-05 2019-01-02 Northwestern University Glyx for use in the treatment of alzheimer's disease, parkinson's disease or huntington's disease
US8951968B2 (en) 2009-10-05 2015-02-10 Northwestern University Methods of treating depression and other related diseases
KR101692275B1 (ko) 2010-02-11 2017-01-04 노오쓰웨스턴 유니버시티 ２차 구조 안정화된 ｎｍｄａ 수용체 조절제 및 그의 용도
CA2789331C (en) 2010-02-11 2017-11-07 Northwestern University Secondary structure stabilized nmda receptor modulators and uses thereof
WO2012021712A1 (en) 2010-08-12 2012-02-16 Tetraphase Pharmaceuticals, Inc. Tetracycline analogs
US9737531B2 (en) 2012-07-12 2017-08-22 Glytech, Llc Composition and method for treatment of depression and psychosis in humans
KR20180095096A (ko) 2011-04-27 2018-08-24 노오쓰웨스턴 유니버시티 알츠하이머병, 헌팅톤병, 자폐증 또는 기타 장애의 치료 방법
US9293690B2 (en) 2011-06-27 2016-03-22 Koninklijke Philips N.V. Ultrasound transducer assembly and method of manufacturing the same
AU2012288626C1 (en) 2011-07-27 2015-09-17 Astrazeneca Ab 2 - (2, 4, 5 - substituted -anilino) pyrimidine derivatives as EGFR modulators useful for treating cancer
US9828384B2 (en) 2013-01-29 2017-11-28 Aptinyx Inc. Spiro-lactam NMDA receptor modulators and uses thereof
US9512134B2 (en) * 2013-01-29 2016-12-06 Aptinyx, Inc. Spiro-lactam NMDA receptor modulators and uses thereof
PE20151437A1 (es) 2013-01-29 2015-10-10 Naurex Inc Moduladores de receptores nmda de espiro-lactama y sus usos
CA2899191A1 (en) 2013-01-29 2014-08-07 Naurex, Inc. Spiro-lactam nmda receptor modulators and uses thereof
WO2014120789A1 (en) 2013-01-29 2014-08-07 Naurex, Inc. Spiro-lactam nmda receptor modulators and uses thereof
BR112018073663A2 (pt) 2016-05-19 2019-04-30 Aptinyx Inc. moduladores de receptores nmda spiro-lactâmicos e seus usos
WO2017201285A1 (en) 2016-05-19 2017-11-23 Aptinyx Inc. Spiro-lactam nmda receptor modulators and uses thereof
PE20190500A1 (es) 2016-08-01 2019-04-10 Aptinyx Inc Moduladores del receptor nmda spiro-lactam y uso de los mismos
CN109890825B (zh) 2016-08-01 2022-03-11 阿普廷伊克斯股份有限公司 螺-内酰胺nmda受体调节剂及其用途
SG11201900546UA (en) 2016-08-01 2019-02-27 Aptinyx Inc Spiro-lactam and bis-spiro-lactam nmda receptor modulators and uses thereof
PE20190503A1 (es) 2016-08-01 2019-04-10 Aptinyx Inc Moduladores del receptor nmda espiro-lactam y uso de los mismos
SG11201900554YA (en) 2016-08-01 2019-02-27 Aptinyx Inc Spiro-lactam nmda modulators and methods of using same

Also Published As

Publication number Publication date
US20160122359A1 (en) 2016-05-05
CL2015002125A1 (es) 2015-12-04
CY1121675T1 (el) 2020-07-31
CL2015002121A1 (es) 2015-12-04
AU2014212484A1 (en) 2015-07-30
SG11201505860XA (en) 2015-08-28
HUE043843T2 (hu) 2019-09-30
WO2014120783A1 (en) 2014-08-07
JP2016506958A (ja) 2016-03-07
BR112015018087B1 (pt) 2022-09-20
EP2951183B1 (en) 2019-03-13
EA032649B1 (ru) 2019-06-28
PH12015501601A1 (en) 2015-10-19
JP6564513B2 (ja) 2019-08-21
AU2014212484B2 (en) 2018-01-04
PL2951183T3 (pl) 2019-08-30
US20160289240A1 (en) 2016-10-06
SI2951183T1 (sl) 2019-07-31
SI3514158T1 (sl) 2023-03-31
NZ709870A (en) 2020-09-25
KR20150110790A (ko) 2015-10-02
PT3514158T (pt) 2023-01-13
MX2015009786A (es) 2015-12-11
EA201591401A1 (ru) 2018-01-31
JP2019019133A (ja) 2019-02-07
US20170231956A1 (en) 2017-08-17
US9504670B2 (en) 2016-11-29
US10441572B2 (en) 2019-10-15
EP2951183A1 (en) 2015-12-09
DK2951183T3 (da) 2019-06-03
US20160368926A1 (en) 2016-12-22
US10441571B2 (en) 2019-10-15
MY188450A (en) 2021-12-09
IL240163B (en) 2020-02-27
US9579304B2 (en) 2017-02-28
IL240163A0 (en) 2015-09-24
ES2935352T3 (es) 2023-03-06
US11077094B2 (en) 2021-08-03
BR112015018087A2 (pt) 2017-07-18
US20220151992A1 (en) 2022-05-19
CA2898861C (en) 2021-07-20
CN105229011A (zh) 2016-01-06
US9512134B2 (en) 2016-12-06
PT2951183T (pt) 2019-06-17
US20180250268A1 (en) 2018-09-06
HK1218417A1 (zh) 2017-02-17
EP3514158B1 (en) 2022-10-12
CA2898861A1 (en) 2014-08-07
CN105229011B (zh) 2018-02-06
EP3514158A1 (en) 2019-07-24
US20180250267A1 (en) 2018-09-06
LT3514158T (lt) 2023-02-10
HRP20221545T1 (hr) 2023-03-03
ES2734405T3 (es) 2019-12-05
US10052308B2 (en) 2018-08-21
KR102280616B1 (ko) 2021-07-21
US20200206189A1 (en) 2020-07-02
PH12015501601B1 (en) 2015-10-19
HRP20190613T1 (hr) 2019-06-28
LT2951183T (lt) 2019-05-27
TR201908596T4 (tr) 2019-07-22
PE20151416A1 (es) 2015-10-10

Similar Documents

Publication Publication Date Title
BR112015018087A8 (pt) composto, composição farmacêutica e uso
BR112015018092A2 (pt) moduladores de receptor de nmda de espiro-lactama e usos dos mesmos
BR112015018094A2 (pt) moduladores de receptor nmda de espiro-lactama e usos dos mesmos
BR112015018089A2 (pt) moduladores de receptor de nmda de espiro-lactama e usos dos mesmos
BR112015018095A2 (pt) moduladores de receptor nmda de espiro-lactama e usos dos mesmos
BR112019001768A2 (pt) moduladores do receptor de spiro-lactamas nmda e usos dos mesmos
CL2015000942A1 (es) Compuestos de benceno sustituido.
UY37645A (es) Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue
BR112016012146A2 (pt) Compostos derivados de aminopiridina como inibidores quinase da família tam, composição farmacêutica compreendendo ditos compostos e uso terapêutico dos mesmos
UY37646A (es) Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue
EA201990428A1 (ru) Спиролактамовые модуляторы nmda-рецептора и их применение
CR20140144A (es) Derivados de estra-1,3,5 (10), 16-tetraen-3-carboxamida, procedimientos para su preparación, preparados farmacéuticos que los contienen, así como su uso para la preparación de medicamentos
CO7160008A2 (es) Derivados de estra- 1,3,5(10),16- tetraeno 3-sustituidos, métodos para su preparación, prepara-ciones farmaceúticas que los contienen, así como su uso para la preparación de medicamentos
PH12016500978A1 (en) Piperazine derivatives having multimodal activity against pain
MX2016007313A (es) Uso de derivados de bencimidazol-prolina.
PH12015502632A1 (en) Cxcr7 receptor modulators
BR112018070603A2 (pt) formulações líquidas de fosfaplatina
EA201400444A1 (ru) Производные 2-оксопиперидинила
EA202091403A1 (ru) Производные 2-оксо-1-пирролидинилимидазотиадиазола
PH12018501991A1 (en) Pharmaceutical composition for use in treating fibrosis
CO2020006552A2 (es) Composiciones farmaceuticas que comprenden safinamida
MX2021014830A (es) Conjugados de compuestos que comprenden nitrogeno heteroaromatico donador de pares de electrones pi.
MX369874B (es) Composicion farmaceutica para el tratamiento de la disfunción erectil a base de un farmaco inhibidor de la enzima pde-5 (fosfodiesterasa tipo 5) en gel.
CL2011002316A1 (es) Compuestos derivados de furopirimidinona, moduladores de receptores trpa1; composicion farmaceutica; y uso en el tratamiento del dolor.

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B25A Requested transfer of rights approved

Owner name: APTINYX INC. (US)

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 29/01/2014, OBSERVADAS AS CONDICOES LEGAIS